Blenrep shows overall survival benefit in head-to-head DREAMM-7 ... - GSK
1 day ago · GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key ...
GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep …
7 hours ago · On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with ...
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
12 hours ago · In boost to GSK's £3B plan for Blenrep, myeloma ADC shows survival edge over J&J's Darzalex. GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears ...
GSK Builds Case for Blenrep with Multiple Myeloma OS Data
14 hours ago · GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster potential for the antibody-drug conjugate. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented ...
GSK hails progress for withdrawn blood cancer drug - Financial …
17 hours ago · GSK hailed progress for its withdrawn blood cancer drug Blenrep on Thursday, raising the prospect of the treatment returning to market after the drugmaker announced positive trial results. Blenrep ...
DREAMM-7 phase III trial shows Blenrep combination nearly tripled ... - GSK
Feb 5, 2024 · GSK plc (LSE/NYSE: GSK) today announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin) combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple myeloma.
GSK’s Blenrep combo meets key survival endpoint in Phase 3 …
16 hours ago · GSK makes case for Blenrep's return with new blood cancer survival data. Ayisha Sharma News Reporter. ... BREAKING NEWS ALERTS 2-3 times a week. ENDPOINTS FDA+ Wed at 2 PM ET.
GSK hails survival results in blood cancer patients with Blenrep
18 hours ago · Thu, 14th Nov 2024 08:54. (Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most ...
GSK hails survival data with revived myeloma drug Blenrep
16 hours ago · Blenrep is still available in some ex-US markets and made modest sales of £3 million ($3.8 million) in the third quarter, a far cry from GSK's previous hopes of turning the drug into a £3 ...
GSK Blenrep shows strong survival benefit in myeloma study
18 hours ago · At 0819 GMT, shares in GSK were down 0.84% at 1,350.5p. Reporting by Josh White for Sharecast.com. GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting ...
- Some results have been removed